600211 西藏药业
已收盘 12-15 15:00:00
资讯
新帖
简况
西藏药业(600211)披露召开2025年第三季度业绩说明会,11月26日股价上涨0.28%
证券之星 · 11-26
西藏药业(600211)披露召开2025年第三季度业绩说明会,11月26日股价上涨0.28%
股市必读:西藏药业(600211)股东户数4.54万户,较上期增加0.57%
证券之星 · 11-03
股市必读:西藏药业(600211)股东户数4.54万户,较上期增加0.57%
西藏药业(600211)2025年三季报简析:净利润同比下降8.85%
证券之星 · 11-01
西藏药业(600211)2025年三季报简析:净利润同比下降8.85%
股市必读:西藏药业三季报 - 第三季度单季净利润同比下降8.46%
证券之星 · 10-31
股市必读:西藏药业三季报 - 第三季度单季净利润同比下降8.46%
每周股票复盘:西藏药业(600211)新活素产能充足预计全年销量略增
证券之星 · 10-12
每周股票复盘:西藏药业(600211)新活素产能充足预计全年销量略增
9月23日西藏药业跌7.06%,国联景颐6个月持有混合A基金重仓该股
证券之星 · 09-23
9月23日西藏药业跌7.06%,国联景颐6个月持有混合A基金重仓该股
异动快报:西藏药业(600211)9月8日13点47分触及涨停板
证券之星 · 09-08
异动快报:西藏药业(600211)9月8日13点47分触及涨停板
每周股票复盘:西藏药业(600211)股东大会通过取消监事会
证券之星 · 09-07
每周股票复盘:西藏药业(600211)股东大会通过取消监事会
西藏药业涨7.13%,华鑫证券一周前给出“买入”评级
证券之星 · 09-05
西藏药业涨7.13%,华鑫证券一周前给出“买入”评级
9月4日西藏药业跌5.36%,国联景颐6个月持有混合A基金重仓该股
证券之星 · 09-04
9月4日西藏药业跌5.36%,国联景颐6个月持有混合A基金重仓该股
9月3日西藏药业涨5.98%,国联景颐6个月持有混合A基金重仓该股
证券之星 · 09-03
9月3日西藏药业涨5.98%,国联景颐6个月持有混合A基金重仓该股
每周股票复盘:西藏药业(600211)拟取消监事会并对外投资6000万美元
证券之星 · 08-31
每周股票复盘:西藏药业(600211)拟取消监事会并对外投资6000万美元
异动快报:西藏药业(600211)8月28日9点42分触及涨停板
证券之星 · 08-28
异动快报:西藏药业(600211)8月28日9点42分触及涨停板
西藏药业最新公告:拟6000万美元投资Accuredit Therapeutics Limited
证券之星 · 08-27
西藏药业最新公告:拟6000万美元投资Accuredit Therapeutics Limited
西藏药业股价下跌1.62% 创新药布局引关注
金融界 · 08-23
西藏药业股价下跌1.62% 创新药布局引关注
西藏药业股价报46.80元 生物制品板块企业受关注
金融界 · 08-22
西藏药业股价报46.80元 生物制品板块企业受关注
每周股票复盘:西藏药业(600211)股东户数减少,净利润下降
证券之星 · 08-17
每周股票复盘:西藏药业(600211)股东户数减少,净利润下降
西藏药业(600211.SH)发布半年度业绩,归母净利润5.67亿元,同比下降8.96%
智通财经 · 08-15
西藏药业(600211.SH)发布半年度业绩,归母净利润5.67亿元,同比下降8.96%
生物制品行业盘中跳水,成大生物跌0.35%
市场透视 · 08-12
生物制品行业盘中跳水,成大生物跌0.35%
脑科学(脑机接口)概念盘中拉升,西藏药业等2只股票涨停
市场透视 · 08-12
脑科学(脑机接口)概念盘中拉升,西藏药业等2只股票涨停
加载更多
公司概况
公司名称:
西藏诺迪康药业股份有限公司
所属行业:
医药制造业
上市日期:
1999-07-21
主营业务:
西藏诺迪康药业股份有限公司的主营业务是生产、销售胶囊剂、生物制剂、颗粒剂、涂膜剂等。公司的主要产品是注射用重组人脑利钠肽(新活素)、单硝酸异山梨酯缓释片(依姆多)、诺迪康胶囊、诺迪康颗粒、雪山金罗汉止痛涂膜剂、十味蒂达胶囊、小儿双清颗粒。公司被认定为国家级高新技术企业。报告期内,公司被评为“农业产业化国家重点龙头企业”。
发行价格:
6.00
{"stockData":{"symbol":"600211","market":"SH","secType":"STK","nameCN":"西藏药业","latestPrice":41.87,"timestamp":1765782000000,"preClose":42.15,"halted":0,"volume":1561444,"delay":0,"changeRate":-0.0066,"floatShares":322000000,"shares":322000000,"eps":3.0442,"marketStatus":"已收盘","change":-0.28,"latestTime":"12-15 15:00:00","open":41.98,"high":42.31,"low":41.82,"amount":65612700,"amplitude":0.0116,"askPrice":41.87,"askSize":58,"bidPrice":41.86,"bidSize":10,"shortable":0,"etf":0,"ttmEps":3.0442,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":5,"adr":0,"adjPreClose":42.15,"symbolType":"stock","openAndCloseTimeList":[[1765762200000,1765769400000],[1765774800000,1765782000000]],"highLimit":46.37,"lowLimit":37.94,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":322319196,"isCdr":false,"pbRate":3.8,"roa":"--","peRate":13.754024,"roe":"17.89%","epsLYR":3.26,"committee":0.207207,"marketValue":13496000000,"turnoverRate":0.0048,"status":1,"floatMarketCap":13496000000},"requestUrl":"/m/hq/s/600211","defaultTab":"news","newsList":[{"id":"2586268168","title":"西藏药业(600211)披露召开2025年第三季度业绩说明会,11月26日股价上涨0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586268168","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586268168?lang=zh_cn&edition=full","pubTime":"2025-11-26 22:16","pubTimestamp":1764166584,"startTime":"0","endTime":"0","summary":"截至2025年11月26日收盘,西藏药业报收于42.43元,较前一交易日上涨0.28%,最新总市值为136.76亿元。该股当日开盘42.32元,最高42.96元,最低42.3元,成交额达1.13亿元,换手率为0.82%。公司近日发布公告称,西藏诺迪康药业股份有限公司将于2025年12月3日15:00-16:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会,介绍公司经营成果、财务状况,并回答投资者关注的问题。会议结束后可通过上证路演中心查看相关内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600038854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0033","600211"],"gpt_icon":0},{"id":"2580235233","title":"股市必读:西藏药业(600211)股东户数4.54万户,较上期增加0.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580235233","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580235233?lang=zh_cn&edition=full","pubTime":"2025-11-03 03:14","pubTimestamp":1762110855,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,西藏药业报收于46.43元,上涨2.93%,换手率2.16%,成交量6.97万手,成交额3.19亿元。当日关注点来自交易信息汇总:10月31日主力资金净流入2339.81万元,占总成交额7.34%。来自股本股东变化:截至2025年9月30日,公司股东户数为4.54万户,较上期增加0.57%。股本股东变化股东户数变动截至2025年9月30日,公司股东户数为4.54万户,较6月30日增加257.0户,增幅0.57%;户均持股数量由上期的7132.0股下降至7092.0股,户均持股市值为33.12万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300000686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600211","BK0033","BK0239"],"gpt_icon":0},{"id":"2580414213","title":"西藏药业(600211)2025年三季报简析:净利润同比下降8.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580414213","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580414213?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:06","pubTimestamp":1761948365,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期西藏药业发布2025年三季报。根据财报显示,西藏药业净利润同比下降8.85%。截至本报告期末,公司营业总收入20.89亿元,同比下降3.96%,归母净利润7.22亿元,同比下降8.85%。按单季度数据看,第三季度营业总收入4.39亿元,同比下降21.79%,第三季度归母净利润1.54亿元,同比下降8.46%。持有西藏药业最多的基金为财通资管健康产业混合A,目前规模为1.18亿元,最新净值1.1645,较上一交易日上涨3.73%,近一年上涨31.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100005287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600211"],"gpt_icon":0},{"id":"2579617761","title":"股市必读:西藏药业三季报 - 第三季度单季净利润同比下降8.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579617761","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579617761?lang=zh_cn&edition=full","pubTime":"2025-10-31 04:19","pubTimestamp":1761855549,"startTime":"0","endTime":"0","summary":"业绩披露要点财务报告西藏药业2025年三季报显示,前三季度公司主营收入20.89亿元,同比下降3.96%;归母净利润7.22亿元,同比下降8.85%;扣非净利润6.68亿元,同比下降2.67%;其中2025年第三季度,公司单季度主营收入4.39亿元,同比下降21.79%;单季度归母净利润1.54亿元,同比下降8.46%;单季度扣非净利润1.25亿元,同比下降23.1%;负债率32.25%,投资收益645.02万元,财务费用-6365.43万元,毛利率93.73%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100006346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600211"],"gpt_icon":0},{"id":"2574457637","title":"每周股票复盘:西藏药业(600211)新活素产能充足预计全年销量略增","url":"https://stock-news.laohu8.com/highlight/detail?id=2574457637","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574457637?lang=zh_cn&edition=full","pubTime":"2025-10-12 01:40","pubTimestamp":1760204419,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘,西藏药业报收于48.89元,较上周的46.7元上涨4.69%。本周,西藏药业10月10日盘中最高价报49.94元。本周关注点公司公告汇总:新活素现有产能可满足需求,预计全年销量较去年略有增长。新活素海外注册正在研究评估中,国际拓展将适时推进。医保谈判价格预计保持稳定,销量无大幅波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600211","BK0033","BK0239"],"gpt_icon":0},{"id":"2569482798","title":"9月23日西藏药业跌7.06%,国联景颐6个月持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2569482798","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569482798?lang=zh_cn&edition=full","pubTime":"2025-09-23 16:31","pubTimestamp":1758616303,"startTime":"0","endTime":"0","summary":"证券之星消息,9月23日西藏药业跌7.06%,收盘报47.5元,换手率5.57%,成交量17.95万手,成交额8.57亿元。重仓西藏药业的公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为国联基金的国联景颐6个月持有混合A。国联景颐6个月持有混合A目前规模为0.91亿元,最新净值0.9635,较上一交易日上涨0.0%,近一年上涨4.4%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092300025864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0239","600211"],"gpt_icon":0},{"id":"2565570088","title":"异动快报:西藏药业(600211)9月8日13点47分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2565570088","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565570088?lang=zh_cn&edition=full","pubTime":"2025-09-08 13:50","pubTimestamp":1757310634,"startTime":"0","endTime":"0","summary":"证券之星9月8日盘中消息,13点47分西藏药业触及涨停板。目前价格55.53,上涨10.0%。其所属行业生物制品目前上涨。该股为医疗器械,民营医院,新冠病毒防治概念热股,当日医疗器械概念上涨2.32%,民营医院概念上涨1.54%,新冠病毒防治概念上涨1.04%。9月8日的资金流向数据方面,主力资金净流入5687.88万元,占总成交额8.76%,游资资金净流出455.63万元,占总成交额0.7%,散户资金净流出5232.25万元,占总成交额8.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090800013463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0239","600211"],"gpt_icon":0},{"id":"2565517440","title":"每周股票复盘:西藏药业(600211)股东大会通过取消监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2565517440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565517440?lang=zh_cn&edition=full","pubTime":"2025-09-07 01:34","pubTimestamp":1757180050,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘,西藏药业报收于50.48元,较上周的47.16元上涨7.04%。本周,西藏药业9月3日盘中最高价报51.68元,股价触及近一年最高点。本周关注点公司公告汇总:西藏药业2025年第一次临时股东大会审议通过取消监事会的议案,同意比例超99.69%。公司公告汇总西藏诺迪康药业股份有限公司于2025年9月2日召开2025年第一次临时股东大会,会议由董事长陈达彬主持,出席股东及代理人共690人,代表有表决权股份总数180,984,839股,占公司有表决权股份总数的56.1508%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700000154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600211","BK0033","BK0239"],"gpt_icon":0},{"id":"2565584095","title":"西藏药业涨7.13%,华鑫证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2565584095","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565584095?lang=zh_cn&edition=full","pubTime":"2025-09-05 16:22","pubTimestamp":1757060533,"startTime":"0","endTime":"0","summary":"今日西藏药业涨7.13%,收盘报50.48元。2025年8月29日,华鑫证券研究员胡博新,吴景欢发布了对西藏药业的研报《公司事件点评报告:主营业务稳健,股权投资创新药打造新增长曲线》,该研报对西藏药业给出“买入”评级。维持“买入”投资评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为78.58%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为首创证券的王斌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090500026481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600211","161027"],"gpt_icon":0},{"id":"2564244353","title":"9月4日西藏药业跌5.36%,国联景颐6个月持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2564244353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564244353?lang=zh_cn&edition=full","pubTime":"2025-09-04 16:18","pubTimestamp":1756973883,"startTime":"0","endTime":"0","summary":"证券之星消息,9月4日西藏药业跌5.36%,收盘报47.12元,换手率5.66%,成交量18.24万手,成交额8.78亿元。重仓西藏药业的公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为国联基金的国联景颐6个月持有混合A。国联景颐6个月持有混合A目前规模为0.91亿元,最新净值0.9656,较上一交易日下跌0.02%,近一年上涨4.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090400025073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0033","600211"],"gpt_icon":0},{"id":"2564234363","title":"9月3日西藏药业涨5.98%,国联景颐6个月持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2564234363","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564234363?lang=zh_cn&edition=full","pubTime":"2025-09-03 16:17","pubTimestamp":1756887463,"startTime":"0","endTime":"0","summary":"证券之星消息,9月3日西藏药业涨5.98%创60日新高,收盘报49.79元,换手率7.64%,成交量24.62万手,成交额12.38亿元。重仓西藏药业的公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为国联基金的国联景颐6个月持有混合A。国联景颐6个月持有混合A目前规模为0.91亿元,最新净值0.9658,较上一交易日下跌0.08%,近一年上涨4.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090300025955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600211","BK0033","BK0239"],"gpt_icon":0},{"id":"2563884027","title":"每周股票复盘:西藏药业(600211)拟取消监事会并对外投资6000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2563884027","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563884027?lang=zh_cn&edition=full","pubTime":"2025-08-31 02:50","pubTimestamp":1756579824,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘,西藏药业报收于47.16元,较上周的46.04元上涨2.43%。本周,西藏药业8月28日盘中最高价报49.28元。本周关注点公司公告汇总:西藏药业拟取消监事会,由审计委员会行使监事会职权。公司公告汇总:公司拟对外投资6,000万美元持有Accuredit Therapeutics Limited 40.82%股权。公司将于2025年9月15日召开第二次临时股东大会,审议《关于对外投资涉及关联交易的议案》。本次交易构成关联交易,尚需股东大会批准,存在研发失败、审批不确定性及商誉减值风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100000332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0239","600211"],"gpt_icon":0},{"id":"2562053770","title":"异动快报:西藏药业(600211)8月28日9点42分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2562053770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562053770?lang=zh_cn&edition=full","pubTime":"2025-08-28 09:45","pubTimestamp":1756345531,"startTime":"0","endTime":"0","summary":"证券之星8月28日盘中消息,9点42分西藏药业触及涨停板。目前价格49.28,上涨10.0%。其所属行业生物制品目前上涨。该股为食品,疫苗,中药概念热股,当日食品概念上涨0.75%,疫苗概念上涨0.71%,中药概念上涨0.64%。8月27日的资金流向数据方面,主力资金净流出3603.14万元,占总成交额9.29%,游资资金净流入1472.43万元,占总成交额3.8%,散户资金净流入2130.71万元,占总成交额5.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800011947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","600211","BK0239"],"gpt_icon":0},{"id":"2562871750","title":"西藏药业最新公告:拟6000万美元投资Accuredit Therapeutics Limited","url":"https://stock-news.laohu8.com/highlight/detail?id=2562871750","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562871750?lang=zh_cn&edition=full","pubTime":"2025-08-27 18:33","pubTimestamp":1756290816,"startTime":"0","endTime":"0","summary":"西藏药业(600211.SH)公告称,公司拟通过全资子公司对Accuredit Therapeutics Limited进行股权投资,投资金额6000万美元,持有其40.82%的股权;公司关联方投资1500万美元,持有其10.20%的股权。该投资构成关联交易,但未构成重大资产重组。此项交易尚须获得股东大会的批准。投资标的公司专注于开发基于LNP和其他非病毒载体的体内基因编辑技术和产品,致力于为全球患者提供创新治疗方案。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700039655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0239","600211"],"gpt_icon":0},{"id":"2561540060","title":"西藏药业股价下跌1.62% 创新药布局引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2561540060","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561540060?lang=zh_cn&edition=full","pubTime":"2025-08-23 04:03","pubTimestamp":1755892985,"startTime":"0","endTime":"0","summary":"西藏药业股价报46.04元,较前一交易日下跌1.62%。盘中最高触及46.70元,最低下探至45.69元,成交量为98714手,成交金额达4.54亿元。西藏药业属于生物制品行业,公司主要从事中成药、藏成药及化学药品的研发、生产和销售。2025年半年报显示,公司投资3亿元参股江苏晨泰医药,持股比例为13.04%。晨泰医药研发的佐利替尼是全球首款针对伴中枢神经系统转移的晚期非小细胞肺癌开展注册临床试验并取得显著成果的药物。8月22日主力资金净流出3891.59万元,近五个交易日累计净流出9780.61万元。风险提示:股市有风险,投资需谨慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/23040352636635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","600211","06978","BK0033","BK1161","BK0239","159992"],"gpt_icon":0},{"id":"2561181244","title":"西藏药业股价报46.80元 生物制品板块企业受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2561181244","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561181244?lang=zh_cn&edition=full","pubTime":"2025-08-22 02:18","pubTimestamp":1755800281,"startTime":"0","endTime":"0","summary":"截至2025年8月21日15时,西藏药业股价为46.80元,较前一交易日下跌0.28元。当日开盘价为48.10元,最高触及48.50元,最低下探至46.39元,成交量为92278手,成交金额达4.36亿元。西藏药业属于生物制品行业,公司注册地位于西藏自治区拉萨市。8月21日早盘交易时段,西藏药业股价曾出现快速回调,在五分钟内跌幅超过2%。当日9点35分,股价报47.40元,成交金额为9604.92万元。资金流向数据显示,西藏药业当日主力资金净流出105万元,占流通市值的0.01%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/22021852599005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["600211","BK0239","BK0033"],"gpt_icon":0},{"id":"2560258629","title":"每周股票复盘:西藏药业(600211)股东户数减少,净利润下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2560258629","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560258629?lang=zh_cn&edition=full","pubTime":"2025-08-17 01:38","pubTimestamp":1755365889,"startTime":"0","endTime":"0","summary":"截至2025年8月15日收盘,西藏药业报收于46.95元,较上周的41.96元上涨11.89%。本周,西藏药业8月13日盘中最高价报51.35元,股价触及近一年最高点。西藏诺迪康药业股份有限公司第八届董事会第十次会议决议公告:会议审议通过了2025年半年度报告全文及摘要、2025年半年度利润分配方案等多项议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081700000149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600211"],"gpt_icon":0},{"id":"2559139259","title":"西藏药业(600211.SH)发布半年度业绩,归母净利润5.67亿元,同比下降8.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2559139259","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559139259?lang=zh_cn&edition=full","pubTime":"2025-08-15 17:26","pubTimestamp":1755249965,"startTime":"0","endTime":"0","summary":"智通财经APP讯,西藏药业(600211.SH)披露2025年半年度报告,报告期公司实现营收16.51亿元,同比增长2.23%;归属于上市公司股东的净利润5.67亿元,同比下降8.96%;扣非净利润5.43亿元,同比增长3.69%;基本每股收益1.76元。公司拟向全体股东每10股派发现金红利8.81元(含税)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1330196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"西藏药业(600211.SH)发布半年度业绩,归母净利润5.67亿元,同比下降8.96%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600211"],"gpt_icon":0},{"id":"2558455697","title":"生物制品行业盘中跳水,成大生物跌0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558455697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558455697?lang=zh_cn&edition=full","pubTime":"2025-08-12 10:40","pubTimestamp":1754966408,"startTime":"0","endTime":"0","summary":"08月12日,生物制品行业盘中跳水,截至10点40分,生物制品行业整体指数下跌1.01%,报6884.300点。从个股上来看,该行业的成分股中,成大生物跌0.35%,长春高新、万泰生物、上海莱士跌幅居前。从资金上来看,截止发稿,生物制品行业主力净流入为-3.27亿,其中西藏药业受到资金热捧,主力净流入2.03亿;拉长时间线来看,该板块近20日主力资金净流入-45.53亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081210400897420a71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081210400897420a71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603392","600211","688739","BK0239"],"gpt_icon":0},{"id":"2558915692","title":"脑科学(脑机接口)概念盘中拉升,西藏药业等2只股票涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2558915692","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558915692?lang=zh_cn&edition=full","pubTime":"2025-08-12 09:50","pubTimestamp":1754963401,"startTime":"0","endTime":"0","summary":"08月12日,脑科学(脑机接口)概念盘中拉升,截至09点49分,脑科学(脑机接口)概念整体指数上涨1.06%,报1023.570点。从个股上来看,该概念的成分股中,麒盛科技涨幅超过10%,西藏药业等2只股票涨停,航天发展、戴维医疗等4只股涨幅超过5%。从资金上来看,截止发稿,脑科学(脑机接口)概念主力净流入为-7739.13万,其中西藏药业受到资金热捧,主力净流入1.83亿;拉长时间线来看,该板块近20日主力资金净流入-85.76亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812095001a6e092ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812095001a6e092ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0033","600211"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765828606689,"stockEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":-0.1226},{"period":"3month","weight":-0.2128},{"period":"6month","weight":0.175},{"period":"1year","weight":0.1695},{"period":"ytd","weight":0.1866}],"compareEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":-0.0307},{"period":"3month","weight":0.0016},{"period":"6month","weight":0.1414},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.154}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"西藏诺迪康药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"45448人(较上一季度增加0.57%)","perCapita":"7092股","listingDate":"1999-07-21","address":"西藏自治区拉萨市堆龙德庆区经济技术开发区A区广州路3号","registeredCapital":"32231万元","survey":" 西藏诺迪康药业股份有限公司的主营业务是生产、销售胶囊剂、生物制剂、颗粒剂、涂膜剂等。公司的主要产品是注射用重组人脑利钠肽(新活素)、单硝酸异山梨酯缓释片(依姆多)、诺迪康胶囊、诺迪康颗粒、雪山金罗汉止痛涂膜剂、十味蒂达胶囊、小儿双清颗粒。公司被认定为国家级高新技术企业。报告期内,公司被评为“农业产业化国家重点龙头企业”。","listedPrice":6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"西藏药业(600211)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供西藏药业(600211)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"西藏药业,600211,西藏药业股票,西藏药业股票老虎,西藏药业股票老虎国际,西藏药业行情,西藏药业股票行情,西藏药业股价,西藏药业股市,西藏药业股票价格,西藏药业股票交易,西藏药业股票购买,西藏药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"西藏药业(600211)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供西藏药业(600211)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}